About Vitae Pharmaceuticals (NASDAQ:VTAE)
Vitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biopharmaceuticals
- Sub-Industry: N/A
- Symbol: NASDAQ:VTAE
- CUSIP: N/A
- Web: vitaepharma.com/
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -11.35
- P/E Growth: 0.00
- Net Margins: -318,350.20%
- Return on Equity: -53.70%
- Return on Assets: -49.85%
- Current Ratio: 12.83%
- Quick Ratio: 12.83%
Frequently Asked Questions for Vitae Pharmaceuticals (NASDAQ:VTAE)
What is Vitae Pharmaceuticals' stock symbol?
Vitae Pharmaceuticals trades on the NASDAQ under the ticker symbol "VTAE."
How were Vitae Pharmaceuticals' earnings last quarter?
Vitae Pharmaceuticals Inc (NASDAQ:VTAE) released its earnings results on Wednesday, August, 3rd. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.41) by $0.05. Vitae Pharmaceuticals had a negative net margin of 318,350.20% and a negative return on equity of 53.70%. The firm's revenue was down 98.0% on a year-over-year basis. During the same period last year, the business posted ($0.45) earnings per share. View Vitae Pharmaceuticals' Earnings History.
Who are some of Vitae Pharmaceuticals' key competitors?
Some companies that are related to Vitae Pharmaceuticals include Biogen (BIIB), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Abcam Plc (ABC), Anika Therapeutics (ANIK), Myovant Sciences Ltd (MYOV), Syros Pharmaceuticals (SYRS), Sinovac Biotech (SVA), ChemoCentryx (CCXI), Mirna Therapeutics (SYBX), Syndax Pharmaceuticals (SNDX), Strongbridge Biopharma PLC (SBBP), Fortress Biotech (FBIO), Mereo BioPharma Group PLC (MPH), Kadmon Holdings (KDMN), Peregrine Pharmaceuticals (PPHM), Kamada (KMDA) and Vericel Corporation (VCEL).
How do I buy Vitae Pharmaceuticals stock?
Shares of Vitae Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vitae Pharmaceuticals' stock price today?
MarketBeat Community Rating for Vitae Pharmaceuticals (NASDAQ VTAE)MarketBeat's community ratings are surveys of what our community members think about Vitae Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Vitae Pharmaceuticals stock can currently be purchased for approximately $21.00.
Earnings History for Vitae Pharmaceuticals (NASDAQ:VTAE)Earnings History by Quarter for Vitae Pharmaceuticals (NASDAQ VTAE)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|5/10/2016||Q1||($0.51)||($0.44)||$0.09 million||$0.05 million||View||Listen|
|3/3/2016||Q415||($0.62)||($0.52)||$0.14 million||$0.09 million||View||Listen|
|11/5/2015||Q315||($0.48)||($0.60)||$0.18 million||$0.18 million||View||Listen|
|8/4/2015||Q215||($0.45)||($0.45)||$0.09 million||$0.16 million||View||Listen|
|5/12/2015||Q115||($0.33)||($0.47)||$0.16 million||$0.15 million||View||Listen|
|3/31/2015||Q414||($0.45)||($0.40)||$0.19 million||$0.16 million||View||Listen|
|11/12/2014||Q3||($0.13)||($1.03)||$6.39 million||$6.18 million||View||Listen|
Earnings Estimates for Vitae Pharmaceuticals (NASDAQ:VTAE)
2017 EPS Consensus Estimate: ($1.29)
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Vitae Pharmaceuticals (NASDAQ:VTAE)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Insider Ownership Percentage: 14.80%Insider Trades by Quarter for Vitae Pharmaceuticals (NASDAQ:VTAE)
Institutional Ownership Percentage: 72.58%
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/14/2016||Adage Capital Partners Gp, L.L||Major Shareholder||Sell||1,025,000||$20.85||$21,371,250.00|| |
|9/14/2016||Jeffrey S Hatfield||CEO||Sell||50,000||$20.81||$1,040,500.00|| |
|3/21/2016||Donald J Hayden Jr||Director||Sell||16,130||$7.42||$119,684.60|| |
|12/29/2015||Donald J. Hayden, Jr.||Director||Sell||16,130||$18.00||$290,340.00|| |
|12/23/2015||Jeffrey S. Hatfield||CEO||Sell||22,524||$17.00||$382,908.00|| |
|9/21/2015||Donald J. Hayden, Jr.||Director||Sell||16,130||$17.00||$274,210.00|| |
|9/29/2014||Peter Barrett||Director||Buy||37,500||$8.00||$300,000.00|| |
|9/29/2014||Venrock Management Iii Llc||Major Shareholder||Buy||772,333||$8.00||$6,178,664.00|| |
Headline Trends for Vitae Pharmaceuticals (NASDAQ:VTAE)
Latest Headlines for Vitae Pharmaceuticals (NASDAQ:VTAE)
Vitae Pharmaceuticals (VTAE) Chart for Wednesday, October, 18, 2017